CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 12 enrolled
Drug / intervention
Atomoxetinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00286949
NCT00286949N/ACompleted
CompareCT.gov

Atomoxetine for the Treatment of Executive Dysfunction in Patients With Parkinson's Disease: A Pilot Open-label Study

Johns Hopkins University·interventional·Posted Feb 6, 2006·Updated Nov 6, 2017

In Brief

A clinical study evaluating Atomoxetine for Parkinson's Disease. Completed, enrolled 12 participants across 1 site.

Detailed Summary

Atomoxetine (Strattera) is a drug that is currently approved for treatment of attention deficit hyperactivity disorder (ADHD) in children and adults. Atomoxetine works to enhance levels of brain chemicals that may be affected in people with executive dysfunction, (difficulties with organization, task completion, and priority setting). Thus, atomoxetine has the potential to improve executive dysfunction in people with Parkinson's disease (PD). The goal of this study is to provide preliminary data on the effectiveness and tolerability of atomoxetine for the treatment of executive dysfunction in patients with PD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesUnited States
CollaboratorsEli Lilly and Company

Timeline

N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 6, 2006
Enrollment StartJan 6, 2005
Primary CompletionJun 30, 2008
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 20.4 years ago

Interventions

Atomoxetinedrug

Open Label uncontrolled active Drug intervention